164 related articles for article (PubMed ID: 38587388)
21. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
Desborough M; Hadjinicolaou AV; Chaimani A; Trivella M; Vyas P; Doree C; Hopewell S; Stanworth SJ; Estcourt LJ
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012055. PubMed ID: 27797129
[TBL] [Abstract][Full Text] [Related]
22. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.
Bisi JE; Sorrentino JA; Roberts PJ; Tavares FX; Strum JC
Mol Cancer Ther; 2016 May; 15(5):783-93. PubMed ID: 26826116
[TBL] [Abstract][Full Text] [Related]
23. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Weiss JM; Csoszi T; Maglakelidze M; Hoyer RJ; Beck JT; Domine Gomez M; Lowczak A; Aljumaily R; Rocha Lima CM; Boccia RV; Hanna W; Nikolinakos P; Chiu VK; Owonikoko TK; Schuster SR; Hussein MA; Richards DA; Sawrycki P; Bulat I; Hamm JT; Hart LL; Adler S; Antal JM; Lai AY; Sorrentino JA; Yang Z; Malik RK; Morris SR; Roberts PJ; Dragnev KH;
Ann Oncol; 2019 Oct; 30(10):1613-1621. PubMed ID: 31504118
[TBL] [Abstract][Full Text] [Related]
24. Current strategies for managing myelosuppression in patients with cancer.
Rostad ME
Oncol Nurs Forum; 1991 Mar; 18(2 Suppl):7-15. PubMed ID: 1904577
[TBL] [Abstract][Full Text] [Related]
25. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
26. Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis.
Adams A; Scheckel B; Habsaoui A; Haque M; Kuhr K; Monsef I; Bohlius J; Skoetz N
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD012633. PubMed ID: 35724934
[TBL] [Abstract][Full Text] [Related]
27. Drug-induced myelosuppression : diagnosis and management.
Carey PJ
Drug Saf; 2003; 26(10):691-706. PubMed ID: 12862504
[TBL] [Abstract][Full Text] [Related]
28. Cell cycle arrest: A breakthrough in the supportive care of older cancer patients.
Falandry C; List A; Balducci L
J Am Geriatr Soc; 2023 Jul; 71(7):2297-2307. PubMed ID: 37036091
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy-associated hematopoietic toxicity.
Kuhn JG
Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S4-7. PubMed ID: 12166034
[TBL] [Abstract][Full Text] [Related]
30. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.
Daniel D; Kuchava V; Bondarenko I; Ivashchuk O; Reddy S; Jaal J; Kudaba I; Hart L; Matitashvili A; Pritchett Y; Morris SR; Sorrentino JA; Antal JM; Goldschmidt J
Int J Cancer; 2021 May; 148(10):2557-2570. PubMed ID: 33348420
[TBL] [Abstract][Full Text] [Related]
31. Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).
Cheng Y; Wu L; Huang D; Wang Q; Fan Y; Zhang X; Fan H; Yao W; Liu B; Yu G; Pan Y; Xu F; He Z; Dong X; Ma R; Min X; Ge X; Chen H; Liu Q; Hu Y; Liu Y; Yang C; Yang Y; Li X; Zhou L
Lung Cancer; 2024 Feb; 188():107455. PubMed ID: 38224653
[TBL] [Abstract][Full Text] [Related]
32. Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings.
Goldschmidt J; Monnette A; Shi P; Venkatasetty D; Lopez-Gonzalez L; Huang H
Future Oncol; 2022 Nov; 18(35):3881-3894. PubMed ID: 36377828
[TBL] [Abstract][Full Text] [Related]
33. The role of myelopoietic growth factors in managing cancer in the elderly.
Balducci L; Carreca I
Drugs; 2002; 62 Suppl 1():47-63. PubMed ID: 12479594
[TBL] [Abstract][Full Text] [Related]
34. Current and future use of hematopoietic growth factors in cancer medicine.
Mughal TI
Hematol Oncol; 2004 Sep; 22(3):121-34. PubMed ID: 15991222
[TBL] [Abstract][Full Text] [Related]
35. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
Fernández-Teruel C; Lubomirov R; Fudio S
J Clin Pharmacol; 2021 Sep; 61(9):1206-1219. PubMed ID: 33914350
[TBL] [Abstract][Full Text] [Related]
36. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
39. Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy.
Bokemeyer C; Honecker F; Wedding U; Späth-Schwalbe E; Lipp HP; Kolb G;
Onkologie; 2002 Feb; 25(1):32-9. PubMed ID: 11893881
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
